Porvair adapting manufacture in the fight against Covid-19

New Delhi, April 06, 2020: In response to Government calls for businesses to support in the production and supply of ventilators and ventilator components, we are proud to announce that Porvair has rapidly adapted some its manufacturing processes in order to join forces in the fight against Covid-19.

Ventilator and breathing apparatus:

  • Our Segensworth Division has been selected to support Project Oyster (the British Consortium of carmakers, Formula One teams, and airplane manufacturers) who has been urged to build 10,000 ventilators. Porvair will be supplying flat discs to be used as air filters, to protect against dust ingestion.
  • Our Wrexham Division is manufacturing filter components for several of the organisations who are now building breathing apparatus to hospitals.
  • Our Caribou Division ismanufacturing and supplying critical porous metal parts for use within ventilators, clinical analysers and respirators.

Medical testing

  • Our Sciences Division has increased production of millions of pipette tips to be used in the United States for their Covid-19 testing kits, as well as supplying consumables for dozens of US testing laboratories.
  • We have supplied bulk filtration media to one of our German distributors to be manufactured into filters for the German Covid-19 testing programme.
  • Our Wrexham Division is undertaking a rapid development project to use existing DNA extraction products and use the technology to design and manufacture RNA extraction kits.

Pharmaceutical production

  • We are supplying chromatography bed supports and pharmaceutical grade water to pharmaceutical customers whose production is increasing.
  • Our sister company Seal Analytical are supplying water quality testing kits and general industrial filters to pharmaceutical and chemical reagent customers for their requirements.

Whilst we have proven that we can rapidly adapt processes to cater for these critical industries, please be rest assured that we continue to manufacture our broad portfolio of products into our established markets, including aerospace and defence, nuclear, food and beverage and microelectronics.

Corporate Comm India (CCI Newswire)

The Pharma Times News Bureau

Share
Published by
The Pharma Times News Bureau

Recent Posts

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

5 hours ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

23 hours ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

4 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

4 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

5 days ago